TG Therapeutics Inc (TGTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.49B
Last updated: Nov 17, 2026 at 4:41 PM ET
TG Therapeutics Inc (TGTX) Stock Chart
TG Therapeutics (TGTX) has a latest price of $62.71 on Nov 17, 2026, 7.8% below its 52-week high of $68.03. Its price rose 102.3% over the past 12 months. The month-end price rose 1,043.6% over the 10 years through Oct 2026, a compound annual rate of 27.6%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $61.18 in Oct 2026 and its lowest $4.10 in Dec 2018, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart TGTX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for TGTX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 21.3%, and over 6 months it rose 59.0%. The month-end price rose 691.5% over the 3 years through Oct 2026, a compound annual rate of 99.3%.
| Period | Change |
|---|---|
| 1 month | +17.7% |
| 3 months | +21.3% |
| 6 months | +59.0% |
| 12 months | +102.3% |
| 12 months, with dividends | +102.3% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +691.5% | +99.3% |
| 5 years | +96.0% | +14.4% |
| 10 years | +1,043.6% | +27.6% |
Price by Year
Its best calendar year was 2020, when the price rose 368.6%, and its weakest was 2021, when it fell 63.5%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $61.18 | +105.2% |
| 2025 | $29.81 | -1.0% |
| 2024 | $30.10 | +76.2% |
| 2023 | $17.08 | +44.4% |
| 2022 | $11.83 | -37.7% |
| 2021 | $19.00 | -63.5% |
| 2020 | $52.02 | +368.6% |
| 2019 | $11.10 | +170.7% |
| 2018 | $4.10 | -50.0% |
| 2017 | $8.20 | +76.3% |
Trading Range
The price is 10.1% above its 50-day average of $56.97 and 37.2% above its 200-day average of $45.71.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $62.71 | |
| 52-week high | $68.03 | -7.8% |
| 52-week low | $26.76 | +134.3% |
| 50-day average | $56.97 | +10.1% |
| 200-day average | $45.71 | +37.2% |
Price Risk
Over 3 years, its largest fall from a peak was 42.0%.
| Measure | Value |
|---|---|
| 1-year beta | 0.70 |
| Largest fall, 1 year | -21.8% |
| Largest fall, 3 years | -42.0% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About TGTX
What is TGTX's 1-year price change?
TG Therapeutics's price rose 102.3% over the past 12 months. With dividends included, the 12-month total return was 102.3%.
What is TGTX's 5-year price change?
TG Therapeutics's month-end price rose 96.0% over the 5 years through Oct 2026, a compound annual rate of 14.4%. These figures leave out dividends.
What is TGTX's 52-week high and low?
TG Therapeutics's 52-week high is $68.03 and its 52-week low is $26.76. Its latest price of $62.71 on Nov 17, 2026 is 7.8% below the high.
What is TGTX's beta?
TG Therapeutics's 1-year beta against the S&P 500 is 0.70, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 21.8%.
Is the TGTX chart free?
Yes. Advanced Charting for TGTX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
TGTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors